Institute to Speed Up Cancer Drug Development
Network - Winter 2012
A major new research institute at MD Anderson will blend the best attributes of academic research and the biotech industry to identify and test new cancer targets, convert scientific knowledge into new cancer drugs and advance these drugs through innovative clinical trials. Researchers will also investigate complementary diagnostics for cancer patients via multidisciplinary collaboration.
The new Institute for Applied Cancer Science will be led by Giulio Draetta, M.D., Ph.D., and Lynda Chin, M.D. Its goal — building an “expressway” for speedier drug development — would be impossible without the strength of MD Anderson’s 18,000-member workforce, notes Ronald DePinho, M.D., president.
“It’s a great day for cancer patients and a dark day for cancer,” DePinho said at the institute’s announcement in late November.